Alaunos Therapeutics, Inc. Form SCHEDULE 13D — Oct 15, 2026
Fairmount Funds Management, its funds, and principals Peter Harwin and Tomas Kiselak filed a Schedule 13D disclosing 19.99% beneficial ownership (858,789 shares) of Alaunos Therapeutics following the October 13, 2026 merger with Velaris Therapeutics. The disclosure reveals a ~$350 million PIPE financing that closed October 14, 2026, in which Alaunos sold 687,789 common shares and 243,063 Series C preferred shares. Fairmount's aggregate purchase price for its securities is over $100 million, with additional preferred shares convertible into more than 174 million common shares subject to a 19.99% cap.
Key figures
- Shares Outstanding
- 3440670
- Merger close date
- 2026-10-13
- Lockup period days
- 180
- Pipe gross proceeds
- $350 million
- Financing close date
- 2026-10-14
- Shares common direct
- 687789
- Shares beneficially owned
- 858789
- Beneficial ownership limit
- 19.99% (drops to 9.99% at 9.0% ownership)
- Preferred conversion ratio
- 1,000 common shares per preferred share
- Aggregate purchase price usd
- $100,199,073.47
- Beneficial ownership percent
- 19.99%
- Series b conversion shares excluded
- 105286000
- Series c conversion shares excluded
- 171000
- Series c fund2 conversion shares excluded
- 52239000
- Series c coinvest conversion shares excluded
- 16554000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.